文献速递胸部肿瘤

新型患者来源肺癌模型揭示NRG1融合阳性癌症中抑制HER3和MTOR信号通路为治疗策略

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
PubMed 文献 · J Thorac Oncol · 2021-04-08

本研究建立了NRG1重排肺腺癌的患者来源异种移植(PDX)和细胞系模型(LUAD-0061AS3,SLC3A2-NRG1),首次报道了NRG1驱动肿瘤的配对体内外模型。抗HER3抗体GSK2849330可抑制模型生长;转录组分析显示NRG1融合肺肿瘤中MTOR通路激活,且LUAD-0061AS3细胞对MTOR抑制剂比乳腺癌细胞系MDA-MB-175-VII更敏感,雷帕霉素在体内抑制PDX肿瘤生长。研究提示MTOR通路是NRG1融合肺腺癌的候选脆弱点,且下游致癌信号存在异质性。

要点

  • NRG1融合肺腺癌中MTOR通路激活,抑制MTOR可抑制模型生长。
  • 抗HER3抗体GSK2849330可减少NRG1驱动模型生长。
  • NRG1融合癌症下游信号存在异质性,可能具肿瘤类型依赖性。

核心结论

  • MTOR通路是NRG1融合阳性肺腺癌的候选脆弱点,值得进一步临床前评估。
  • NRG1重排癌症下游致癌信号存在异质性,可能呈肿瘤类型依赖性。

研究设计与样本

  • 从NRG1重排肺腺癌样本建立PDX和细胞系模型。
  • 进行转录组、蛋白质组和生化分析以识别激活通路。
  • 开展疗效研究评估HER3和MTOR靶向治疗。

主要发现

  • 建立了一对PDX和细胞系模型LUAD-0061AS3(SLC3A2-NRG1),为首次报道的NRG1驱动肿瘤配对体内外模型。
  • 抗HER3抗体GSK2849330减少LUAD-0061AS3模型生长。
  • NRG1融合肺肿瘤样本中MTOR通路激活。
  • LUAD-0061AS3细胞中MTOR效应子S6和4EBP1磷酸化高于人支气管上皮细胞和乳腺癌细胞系MDA-MB-175-VII(DOC4-NRG1融合)。
  • LUAD-0061AS3细胞对MTOR抑制剂比MDA-MB-175-VII细胞更敏感;雷帕霉素在体内阻断LUAD-0061AS3 PDX肿瘤生长。

临床怎么用

  • NRG1融合肺腺癌患者中可考虑评估MTOR通路抑制作为潜在治疗策略。
  • ERBB导向治疗失败后,MTOR抑制可能提供额外治疗选择。
  • 不同肿瘤类型的NRG1融合下游信号异质性需在治疗选择时加以考虑。

局限性

  • 结果基于临床前模型,需进一步临床前评估。
  • NRG1重排癌症下游信号异质性的治疗意义需额外研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: NRG1 rearrangements produce chimeric ligands that subvert the ERBB pathway to drive tumorigenesis. A better understanding of the signaling networks that mediate transformation by NRG1 fusions is needed to inform effective therapeutic strategies. Unfortunately, this has been hampered by a paucity of patient-derived disease models that faithfully recapitulate this molecularly defined cancer subset. METHODS: Patient-derived xenograft (PDX) and cell line models were established from NRG1-rearranged lung adenocarcinoma samples. Transcriptomic, proteomic, and biochemical analyses were performed to identify activated pathways. Efficacy studies were conducted to evaluate HER3- and MTOR-directed therapies. RESULTS: We established a pair of PDX and cell line models of invasive mucinous lung adenocarcinoma (LUAD) (LUAD-0061AS3, SLC3A2-NRG1), representing the first reported paired in vitro and in vivo model of NRG1-driven tumors. Growth of LUAD-0061AS3 models was reduced by the anti-HER3 antibody GSK2849330. Transcriptomic profiling revealed activation of the MTOR pathway in lung tumor samples with NRG1 fusions. Phosphorylation of several MTOR effectors (S6 and 4EBP1) was higher in LUAD-0061AS3 cells compared with human bronchial epithelial cells and the breast cancer cell line MDA-MB-175-VII (DOC4-NRG1 fusion). Accordingly, LUAD-0061AS3 cells were more sensitive to MTOR inhibitors than MDA-MB-175-VII cells and targeting the MTOR pathway with rapamycin blocked growth of LUAD-0061AS3 PDX tumors in vivo. In contrast, MDA-MB-175-VII breast cancer cells had higher MAPK pathway activation and were more sensitive to MEK inhibition. CONCLUSIONS: We identify the MTOR pathway as a candidate vulnerability in NRG1 fusion-positive lung adenocarcinoma that may warrant further preclinical evaluation, with the eventual goal of finding additional therapeutic options for patients in whom ERBB-directed therapy fails. Moreover, our results uncover heterogeneity in downstream oncogenic signaling among NRG1-rearranged cancers, possibly tumor type-dependent, the therapeutic significance of which requires additional investigation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Odintsov I, Mattar MS, Lui AJW, et al. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. J Thorac Oncol. 2021. PMID: 33839363. doi:10.1016/j.jtho.2021.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。